

**Docket No. 09-035-23**

**Utah Office of Consumer Services Witness:**

**Daniel J. Lawton**

**October 22, 2009**



**SURREBUTTAL TESTIMONY OF  
DANIEL J. LAWTON**

1 **Q. PLEASE STATE YOUR NAME AND BUSINESS ADDRESS.**

2 A. My name is Daniel J. Lawton. My business address is 701 Brazos St, Suite 500, Austin,  
3 Texas 78701.

4 **Q. ARE YOU THE SAME DANIEL J. LAWTON WHO PREVIOUSLY FILED**  
5 **DIRECT TESTIMONY IN THIS PROCEEDING?**

6 A. Yes, I am.

7 **Q. WHAT IS THE PURPOSE OF YOUR SURREBUTTAL TESTIMONY?**

8 A. The purpose of this surrebuttal testimony is to respond to the October 2009 rebuttal  
9 testimony of Company witnesses Bruce N. Williams and Samuel Hadaway.

10 **Q. WHAT COMMENTS DO YOU HAVE WITH REGARD TO MR. WILLIAMS'**  
11 **REBUTTAL TESTIMONY?**

12 A. I address Mr. Williams' testimony at pages 5:99 through 7:128. Specifically, Mr.  
13 Williams' claims that my "Exhibit OCS 1.10 takes a much more superficial approach to  
14 the calculation of financial metrics than employed by the rating agencies."<sup>1</sup> My Exhibit  
15 OCS 1.10 shows that the resulting financial metrics at my recommended 10% equity  
16 return are not very different from the results generated by the Company's requested  
17 11.0% equity return. Thus, granting an equity return at 10% allows the Company to  
18 maintain a financial integrity level consistent with that proposed by RMP in its  
19 application.

20 In addition, the resulting financial metrics, whether at an 11% equity return or the 10%  
21 equity return I recommend, do not impair RMP's financial integrity. Further, Mr.  
22 Williams' own evidence supports the maintenance of a single A bond rating, which states  
23 that the "...A- corporate credit rating (CCR) on PacifiCorp reflects its 'excellent'

---

<sup>1</sup> Rebuttal Testimony B. Williams at 6:110-111.

24 business profile, evidenced by a diverse and growing service territory, and an  
25 ‘aggressive’ financial profile that reflects a large capital program and the need to shore up  
26 its cash flow metrics.”<sup>2</sup>

27 Rating agencies are aware of how the regulatory process works and recognize that cash  
28 flow improvement follows the inclusion of capital additions in rates. Again, Mr.  
29 Williams’ own evidence states, “Standard & Poor’s Rating Services expects that  
30 management will achieve cash flow metrics more consistent with an ‘A’ category rating  
31 over the next several years.”<sup>3</sup>

32 **Q. IS IT UNUSUAL FOR A COMPANY’S CASH FLOW METRICS TO BE BELOW**  
33 **RATINGS GUIDELINES DURING LARGE CAPITAL EXPANSION PERIODS?**

34 A. No it is not unusual, moreover it does not mean a bond rating downgrade will result. As  
35 noted above, rating agencies are fully informed of the regulatory process and how cash  
36 flow projections change when capital projects are completed and included in rates.

37 As I discussed in my direct testimony at 34:852, RMP fully intends to take advantage of  
38 newly enacted Utah Code Ann.§54-7-13.4, “Alternative cost recovery for major plant  
39 additions” and include major additions in rates without the need for major rate  
40 proceedings. Such single issue rate setting will accelerate cash flow improvement. As  
41 noted earlier, ratings agencies also recognize this will improve cash flow of the next  
42 several years.<sup>4</sup>

43 **Q. AT PAGE 6, LINES 110-117, OF HIS REBUTTAL MR. WILLIAMS CRITICIZES**  
44 **YOU FOR FAILING TO IMPUTE \$1 BILLION OF ADDITIONAL DEBT AND**  
45 **ABOUT \$75 MILLION OF ADDITIONAL INTERST EXPENSE IN YOUR**  
46 **FINANCIAL METRICS ANALYSIS – DO YOU HAVE ANY COMMENTS?**

47 A. Yes. While it is true that for many years Standard & Poor’s has viewed certain  
48 obligations such as power supply agreements (PPA) as a debt like financial obligation for  
49 purposes of calculating financial metrics that does not mean that a regulator should do the

---

<sup>2</sup> Rebuttal Testimony B. Williams Exhibit RMP \_\_ (BNW-1R) page 2 of 10.

<sup>3</sup> *Id.* at 2-3.

<sup>4</sup> *Id.*

50 same. Instead, in rate setting and evaluation of cost obligations – regulatory authorities  
51 consider only the just and reasonable costs in setting rates. Thus, the inclusion of  
52 additional debt obligations and phantom interest expense in the evaluation of a reasonable  
53 return is just not appropriate. Certainly, utility companies would object to including  
54 phantom interest expense as an additional tax deductible expense to lower revenue  
55 requirements.

56 Again, Mr. Williams misses the point of my Exhibit OCS 1.10. I did not include  
57 phantom debt or interest in the financial metric calculation in either the Company’s 11%  
58 equity return request or my proposed 10% equity return request and the result is a  
59 marginal difference in results. If the same phantom debt and interest is included in the  
60 Company’s request and my proposal – the relative difference between an 11.0% and a  
61 10% equity return remains the same.

62 **Q. PLEASE CONCLUDE YOUR COMMENTS REGARDING MR. WILLIAMS**  
63 **REBUTTAL TESTIMONY.**

64 A. The resulting financial metrics of the Company when a 10% equity return is authorized  
65 continue to support an “A” rating. Moreover, various financial measures change only  
66 marginally when my recommended 10% equity return is employed. While it is true that  
67 S&P’s view of a standalone PacifiCorp has current financial metrics consistent with a  
68 “BBB” rating, S&P also recognizes that one of the benefits of the MidAmerican Energy  
69 Holdings, Co. (“MEHC”) purchase is additional credit support for PacifiCorp. This was  
70 a claimed benefit of the PacifiCorp acquisition by MEHC. Further, it is true that the  
71 capital expansion of PacifiCorp and specifically RMP is being included in rates and  
72 enhancing cash flow metrics.

73 The bottom line is that a 10% equity return will not harm RMP’s financials as the  
74 financial metrics continue to support its “A” rating.

75 **Q. DO YOU HAVE ANY COMMENTS REGARDING DR. HADAWAY’S**  
76 **REBUTTAL TESTIMONY?**

77 A. Yes, I have a number of comments.

78 **Q. HAS DR. HADAWAY UPDATED HIS COST OF CAPITAL ANALYSIS?**

79 A. Yes he has. While Dr. Hadaway continues to support his 11.0% recommended equity  
80 return – his own updates show declining capital costs.<sup>5</sup> Dr. Hadaway’s own updates  
81 indicate his initial DCF analysis should be lowered by about 50 basis points and his  
82 initial risk premium results should be lowered by about 30 to 40 basis points.

83 Despite these declines in capital costs and Dr. Hadaway’s acknowledgement that utility  
84 interest rates have dropped,<sup>6</sup> he insists on maintaining his 11.0% equity return – because  
85 his original recommendation of 11.0% “...was never based on those extreme data.”<sup>7</sup>

86 **Q. IF DR. HADAWAY’S 11.0% EQUITY RETURN RECOMMENDATION WAS**  
87 **NOT BASED ON WHAT HE CATEGORIZES AS “EXTREME” RESULTS,**  
88 **WHAT DID HE BASE HIS RECOMMENDATION ON?**

89 A. I relied on Dr. Hadaway’s statements in his direct testimony where he states:

90 “...the lower end of the DCF range and equity risk premium estimates based on  
91 historical risk premium relationships represent very conservative estimates of the  
92 cost of equity. From this perspective, and with consideration of the Company’s  
93 large on-going capital requirements, the minimum fair cost of equity capital for  
94 RMP is 11.0 percent.”<sup>8</sup>

95 The low end of his DCF in the direct testimony is 11.5%.<sup>9</sup> The low end of his historical  
96 risk premium estimates of 10.17% to 10.77% average about 10.5%.<sup>10</sup> Thus, Dr.  
97 Hadaway’s original range was 10.5% - 11.5% and he appears to have selected the 11.0%  
98 midpoint.

---

<sup>5</sup> Rebuttal Testimony Samuel Hadaway at 2:27-35.

<sup>6</sup> *Id.* at 2:41.

<sup>7</sup> *Id.* at 2:43.

<sup>8</sup> Hadaway direct testimony at 35:752-756.

<sup>9</sup> *Id.* at 35.

<sup>10</sup> *Id.*

99 Now, in rebuttal he appears to abandon his direct testimony and claim his 11.0%  
100 recommendation "...was never based on those extreme data."<sup>11</sup> His rebuttal testimony is  
101 not consistent with his direct testimony.

102 **Q. HAD DR. HADAWAY PERFORMED A COMPLETE UPDATE AND**  
103 **EMPLOYED THE LOWER END OF HIS HISTORICAL RISK PREMIUM AND**  
104 **DCF RESULTS IN THE SAME FASHION AS OUTLINED IN HIS DIRECT**  
105 **TESTIMONY, IS AN 11.0% EQUITY RETURN SUPPORTED?**

106 A. No. Dr. Hadaway concedes that the low end of his updated DCF is 11.0%. Dr.  
107 Hadaway's historical risk premium calculations employing the Ibbotson Risk Premium of  
108 3.7% to 5.5% combined with Dr. Hadaway's updated Single "A" debt cost estimate of  
109 5.96% indicates a risk premium estimate of 9.66% to 11.46%. Dr. Hadaway's other  
110 updated historical risk premium estimate shown at his Exhibit \_\_ (SCH-6R) shows a  
111 range of 10.47% to 11.21%. Relying on the lower end of the two risk premium results  
112 indicates a cost of equity of 9.66% to 10.47% or about 10%. Thus, Dr. Hadaway's  
113 updates, if done in the same fashion as his direct testimony, indicate a DCF result of  
114 11.0% and a risk premium result of 10%.

115 The lower end of Dr. Hadaway's analyses is consistent with my recommended range of  
116 9.5% to 10.5%. Moreover, my recommended 10% equity return is consistent with a  
117 corrected update of Dr. Hadaway's analysis.

118 **Q. AT PAGE 14 OF HIS REBUTTAL TESTIMONY DR. HADAWAY STATES**  
119 **THAT CAPM RESULTS SHOULD BE DISMISSED – DID YOU RELY ON THE**  
120 **CAPM RESULTS?**

121 A. No. Dr. Hadaway is attempting to create an issue where no issue exists. If you look at  
122 page 28 of my direct testimony I summarize the results of each analysis. Based on the  
123 range of results, I concluded the "...relevant range of results indicates a cost of equity  
124 from 9.5% to 10.5%, with 10.0% as a midpoint."<sup>12</sup> (Technically the relevant range is  
125 9.52% to 10.62%; I took the liberty of rounding the ranges). By not including any results

---

<sup>11</sup> Hadaway Rebuttal Testimony at 2:43.

<sup>12</sup> Lawton Direct Testimony at 28:718-719.

126 below 9.5% in the “relevant range” I specifically excluded the ECAPM results.  
127 Moreover, at page 27, lines 707-716 of my direct testimony I again pointed out only the  
128 higher end of the ECAPM should be considered reasonable estimates. But, the end result  
129 is that I did not employ any of the ECAPM or CAPM estimates in my estimate of final  
130 relevant cost of equity range for RMP, and my direct testimony is clear on this matter.

131 **Q. AT PAGE 3 OF HIS REBUTTAL TESTIMONY DR. HADAWAY CRITICIZES**  
132 **YOU FOR RESORTING TO THE GEOMETRIC MEAN RISK PREMIUM TO**  
133 **ARRIVE AT A LOWER ESTIMATE OF ROE – DO YOU HAVE ANY**  
134 **COMMENTS?**

135 A. Yes. I did not “resort” to employing the geometric mean risk premium – the geometric  
136 average is the appropriate measure to employ. Moreover, Dr. Hadaway’s direct  
137 testimony at page 34, lines 733 to 735 uses the very same geometric average in his own  
138 risk premium analysis. This is how Dr. Hadaway calculates his 10.17% risk premium  
139 equity return result shown at page 34, line 737, page 35, Table 4, and in part relies upon  
140 this 10.17% result in making his final recommendation.<sup>13</sup>

141 Given Dr. Hadaway’s significant reliance on employing the geometric mean risk  
142 premium – I am baffled by his criticism when I employ the same approach.

143 **Q. AT PAGE 10 OF HIS REBUTTAL TESTIMONY DR. HADAWAY SUGGESTS**  
144 **YOUR RECOMMENDED EQUITY RETURN IS BELOW THE AVERAGE**  
145 **AUTHORIZED RETURNS ALLOWED IN 2009, DO YOU HAVE ANY**  
146 **COMMENTS?**

147 A. Yes. While my recommendation is below the average authorized equity return, it does  
148 not mean my recommendation is not appropriate or is out of line with the main stream.  
149 Obviously, to average 10.29% (Quarter I) or 10.52% (Quarter II) some returns were  
150 below 10.29% or 10.52% and some above. Dr. Hadaway’s analysis of average  
151 authorized equity returns should not dictate whether a specific recommendation is high or  
152 low – each case must be judged on its facts and circumstances. Lastly, if we were to

---

<sup>13</sup> Hadaway Direct Testimony at page 2:38-43.



153 listen to Dr. Hadaway on this matter – then his 11.0% is about 50 basis points above the  
154 average authorized equity returns - but Dr. Hadaway never mentions this.

155 **Q. AT PAGE 4, LINES 86-88 OF DR. HADAWAY’S REBUTTAL TESTIMONY HE**  
156 **STATES “OTHER PARTIES SEEM TO HOLD A MISTAKEN BELIEF THAT**  
157 **EQUITY CAPITAL COSTS FOR UTILITIES HAVE DECREASED, NOT**  
158 **INCREASED, OVER THE PAST SEVERAL MONTHS. THIS CONTENTION IS**  
159 **SIMPLY WRONG”. DO YOU AGREE WITH DR. HADAWAY?**

160 A. No, and once again Dr. Hadaway is inconsistent with the facts and realities of the market.  
161 Dr. Hadaway filed his direct testimony in June 2009. Now, several months later he files  
162 rebuttal testimony and states:

163 My updated discounted cash flow (DCF) analysis indicates an ROE range of 11.0  
164 percent to 11.5 percent, as compared to the DCF range in my June 23, 2009 direct  
165 testimony of 11.5 percent to 12.0 percent. ...This analysis shows that my initial  
166 ROE recommendation was extremely conservative, given then existing market  
167 conditions,...<sup>14</sup>

168 Now, page 2 of his rebuttal concedes equity capital cost as measured by his own analyses  
169 have declined. He even points out how conservative his estimate was given the June  
170 2009 time frame market conditions.

171 At page 4 of his rebuttal testimony, Dr. Hadaway shifts gears and concludes equity  
172 capital costs for utilities have not decreased.<sup>15</sup> Dr. Hadaway is once again arguing  
173 opposite and inconsistent positions albeit on different pages of his rebuttal.

174 **Q. HAS DR. HADAWAY PROVIDED ANY CREDIBLE EVIDENCE THAT WOULD**  
175 **CAUSE YOU TO CHANGE YOUR RECOMMENDATION IN THIS CASE?**

176 A. No. I recommend a 10% equity return and the evidence presented in this case supports a  
177 10% equity return is a just and reasonable result. Moreover, Dr. Hadaway’s own updated  
178 analysis supports a 10% equity return.

---

<sup>14</sup> Rebuttal testimony Hadaway at 2:27-34.

<sup>15</sup> *Id.* at 4:86-89.

179 I have also addressed earlier how Dr. Hadaway's rebuttal testimony is inconsistent with  
180 itself, inconsistent with his direct testimony such that little confidence can be had in his  
181 arguments. Moreover, I have shown how Dr. Hadaway has attempted to raise arguments  
182 or issues that are irrelevant or non-issues or has complained about my reliance on  
183 geometric mean risk premium estimates when he also relied on the same approach.

184 Dr. Hadaway has not rebutted my analysis and recommendations, but instead attempted  
185 to raise arguments that tend to confuse and distort the important issues this Commission  
186 is addressing in this case.

187 **Q. DOES THIS CONCLUDE YOUR TESTIMONY?**

188 **A. Yes.**